stockrow
Friday 6 November 2026
Export TEVA’s income statement to Excel — free account
Teva Pharmaceutical Industries Ltd.
TEVA Healthcare Drug Manufacturers Specialty & Generic
Teva Pharmaceutical Industries Ltd.’s revenue for fiscal 2025 (year ended December 2025) was $17.3 billion, up 4.32% from fiscal 2024.
- Revenue
- −1.90%
- EPS
- −47.2%
- Free cash flow
- −30.3%
- Total debt
- −0.43%
Quarter to September 2026, against a year earlier
42.44
0.66
+1.58%
Follow TEVA
Alert me
| Sep '26 | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
| 6.65% | 9.69% | 21.58% | 21.21% |
+8 more TTM periods Free account |
|
Piotroski F-Score |
6 | 7 | 7 | 8 | |
| 1.27% | 1.77% | 3.99% | 3.52% | ||
ROIC |
4.09% | 4.58% | 6.77% | 6.37% | |
Return on Tangible Assets |
17.34% | 34.62% | 37.48% | 30.85% | |
Average Days of Receivables |
81.28 | 73.63 | 71.38 | 78.44 | |
Free Cash Flow per Share |
1.14 | 1.20 | 1.06 | 1.03 | |
Free Cash Flow |
1,328.00 | 1,401.00 | 1,231.00 | 1,182.00 | |
Capital Expenditures |
(442.00) | (497.00) | (483.00) | (467.00) | |
| Other line items | |||||
Cash ROIC |
4.61% | 5.00% | 4.30% | 4.18% | |
Accounts Receivable Turnover |
4.51 | 4.91 | 5.12 | 5.10 | |
Accounts Payable Turnover |
3.27 | 3.15 | 3.40 | 3.52 | |
Inventory Turnover |
2.47 | 2.45 | 2.59 | 2.69 | |
Average Days of Payables |
116.23 | 120.65 | 113.93 | 111.04 | |
Days of Inventory on Hand |
144.57 | 142.82 | 139.38 | 139.46 | |
Tax Rate |
0.38 | (0.02) | 0.14 | 0.15 | |
Research and Development Expense of Revenue |
10.19% | 9.90% | 5.69% | 5.87% | |
Selling, General and Administrative Expense of Revenue |
24.16% | 23.85% | 23.37% | 23.02% | |
Share Based Compensation of Revenue |
1.00% | 0.97% | 0.96% | 0.91% | |
Operating CF/Net income |
3.49 | 2.68 | 1.10 | 1.17 | |
Depreciation/Fixed assets |
0.26 | 0.25 | 0.25 | 0.25 | |
Capex/Depreciation |
(0.45) | (0.50) | (0.48) | (0.47) | |
Revenue per Share |
14.78 | 14.86 | 15.01 | 15.07 | |
Operating CF per Share |
1.52 | 1.63 | 1.48 | 1.44 | |
Capex per Share |
(0.38) | (0.43) | (0.42) | (0.41) | |
Capex to Sales |
0.03 | 0.03 | 0.03 | 0.03 |
Columns are period end dates · fundamentals updated 5 Nov 2026